Cargando…

Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011

INTRODUCTION: Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor available in France since 2006, is indicated for the treatment of HIV-1 infection in combination with a ritonavir boosted protease inhibitor (PI) in antiretroviral treatment-experienced adult patients. To assess its imp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacombe, Jean-Marc, Goujard, Cecile, Valantin, Marc-Antoine, Cheret, Arnaud, Lahoulou, Rima, Girard, Pierre-Marie, Costagliola, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P249
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225403/ https://www.ncbi.nlm.nih.gov/pubmed/25397525 http://dx.doi.org/10.7448/IAS.17.4.19781

Ejemplares similares

Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
por: Potard, Valérie, et al.
Publicado: (2018)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

Les scores de sévérité des pneumopathies aiguës communautaires sont-ils encore valides pour la pneumopathie à COVID-19 ?
por: Ben Rhouma, C., et al.
Publicado: (2022)

Variations of cardiovascular procedures (diagnostic and therapeutic) in France during COVID-19 epidemic (2020–21): An observational nationwide study
por: Tuppin, P., et al.
Publicado: (2023)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba
por: Kouri, Vivian, et al.
Publicado: (2014)

Characteristics of late presentation of HIV infection in MSM and heterosexual adults in Portugal 2011–2013
por: Shivaji, Tara, et al.
Publicado: (2014)

Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014
por: Rappold, Michaela, et al.
Publicado: (2014)

Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013
por: McFaul, Katie, et al.
Publicado: (2014)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

Outcomes of initial antiretroviral treatment (ART) among recently diagnosed HIV patients in HIV-TR cohort, 2011–2012
por: Korten, Volkan, et al.
Publicado: (2014)

Transmission route and reasons for HIV testing among recently diagnosed HIV patients in HIV-TR cohort, 2011–2012
por: Dokuzoguz, Basak, et al.
Publicado: (2014)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Cohorte de suivi des patients ayant présenté une embolie pulmonaire dans le cadre d’une infection à COVID-19
por: Doutrelon, Caroline, et al.
Publicado: (2023)

Profils d’anticorps dans le plasma de convalescent COVID-19 traité pour traitement de réduction des agents pathogènes par Amotosalen/UVA
por: Corash, Laurence, et al.
Publicado: (2021)

Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials
por: Arribas, Jose, et al.
Publicado: (2014)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer, Danielle
Publicado: (2013)

Experimental data of co-crystals of Etravirine and L-tartaric acid
por: Rekdal, Mikal, et al.
Publicado: (2017)

Future prospectives of sub-Saharan women living with HIV residing in France for more than seven years: prospective pilot study
por: Dimi, Svetlane, et al.
Publicado: (2014)

Factors associated with the continuum of care of HIV-infected patients in Belgium
por: Van Beckhoven, Dominique, et al.
Publicado: (2014)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

CONFISEP : impact du confinement sur la prise en charge des patients atteints de sclérose en plaques
por: Guenot, Maëva, et al.
Publicado: (2021)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Suivi cartographique des prélèvements de produits sanguins et de l’épidémie de la COVID-19
por: Halbout, Philippe-Antoine, et al.
Publicado: (2021)

Pseudo-engelures après vaccination anti-SARS-CoV2 par le vaccin à ARN messager BNT162b2 : nouvelle observation soutenant le rôle de la réponse immunitaire antivirale à l’origine des « COVID toes »
por: Karrakchou, Basma, et al.
Publicado: (2021)

Two years of Truvada for pre-exposure prophylaxis utilization in the US
por: Flash, Charlene, et al.
Publicado: (2014)

Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone
por: Garimella, Tushar, et al.
Publicado: (2014)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Existe-t-il un risque lié à l’utilisation des anti-inflammatoires non stéroïdiens chez les patients atteints de COVID-19 ? Résultats d’une méta-analyse
por: Moore, Nicholas, et al.
Publicado: (2021)

Existe-t-il un effet protecteur de l’aspirine dans la COVID-19 ? Résultats d’une méta-analyse
por: Moore, Nicholas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ub0rukevikkpdruj5kojoi5m31